scispace - formally typeset
J

Jennifer L. Beebe-Dimmer

Researcher at Wayne State University

Publications -  92
Citations -  2395

Jennifer L. Beebe-Dimmer is an academic researcher from Wayne State University. The author has contributed to research in topics: Prostate cancer & Cancer. The author has an hindex of 26, co-authored 92 publications receiving 1820 citations.

Papers
More filters
Journal ArticleDOI

The Epidemiology and Pathogenesis of Neoplasia in the Small Intestine

TL;DR: The pathophysiology of Crohn inflammatory bowel disease and the elevated risk of adenocarcinoma demonstrate the significance of the impaired integrity of the mucosal barrier and of aberrant immune responses to luminal indigenous and potentially pathogenic microorganisms.
Journal ArticleDOI

Current Perspective on the Global and United States Cancer Burden Attributable to Lifestyle and Environmental Risk Factors

TL;DR: It is estimated that a maximum of 60% of cancer deaths in the United States may be attributed to eight risk factors: tobacco, alcohol, ionizing and solar radiations, occupations, infectious agents, obesity, and physical inactivity.
Journal ArticleDOI

Biliary tract cancer incidence and trends in the United States by demographic group, 1999-2013

TL;DR: A recent US study reported increasing GBC incidence among people younger than 45 years and blacks; however, it did not examine trends for other biliary tract sites.
Journal ArticleDOI

Risk of second primary tumors in men diagnosed with prostate cancer: A population‐based cohort study

TL;DR: The survival of men diagnosed with prostate cancer has improved over time, and the current 10‐year relative survival rate is 99.7%.
Journal ArticleDOI

Mesothelioma in the United States: a Surveillance, Epidemiology, and End Results (SEER)-Medicare investigation of treatment patterns and overall survival.

TL;DR: Irrespective of surgical resection, mesothelioma patients receiving some form of chemotherapy survived longer than patients who did not, with an additional survival benefit among those patients receiving multimodal treatment.